UPyTher attracts seed financing to advance the treatment of peritoneal cancer

UPyTher has secured a substantial amount from a group of investors with Essential Investments, Brabant Development Agency (BOM) and TTT Medtech.

UPyTher, a start-up pioneering innovative therapies for the treatment of peritoneal cancer patients, has received funding from a group of investors. To date, peritoneal cancer often leads to treatment failure and increased mortality in patients with colorectal, ovarian and gastric cancer.

The amount of the investment has not been disclosed. According to the start-up, the investment enables the preclinical development of UPyTher's lead product UPT-211 for the treatment of peritoneal metastases from colorectal cancer. The company is now preparing the first clinical studies.

UPyTher B.V. is a spinout of Eindhoven University of Technology that focuses on turning peritoneal cancer into a treatable disease. UPyTher builds on patented polymer technology and pioneers innovative therapies specifically designed and developed for use in the abdominal cavity. With a chemo gel, UPyTher aims to set a new standard for intraperitoneal therapy that offers life-saving options for patients and makes intraperitoneal therapy simple, safe and effective.

“In combination with the recently awarded OPZuid funding, this investment will accelerate the preclinical development program for UPT-211,” says CEO Geert van Almen. “This funding allows us to demonstrate the effectiveness and safety of our patented technology. It can serve as a platform for the development of a broad portfolio of innovative and effective therapeutics for the treatment of peritoneal cancer and other primary cancers such as ovarian and gastric cancer, as well as several other conditions in the abdominal cavity,” added CTO Peter Paul Fransen.

Floris Hamel, Investment Manager at BOM, is convinced that UPyTher's products have the potential to really improve the lives of patients diagnosed with peritoneal cancer. “This start-up can change the current treatment paradigm by making intraperitoneal therapy simple, safe and effective.”
 

“This start-up can change the current treatment paradigm by making intraperitoneal therapy simple, safe and effective.”

Floris Hamel, Investment Manager at BOM